Gross Profit Trends Compared: Takeda Pharmaceutical Company Limited vs Exelixis, Inc.

Gross Profit Trends: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis compares the gross profit trajectories of Takeda Pharmaceutical Company Limited and Exelixis, Inc. over the past decade. Takeda, a Japanese multinational, consistently showcases robust financial health, with gross profits soaring from approximately 1.26 trillion in 2014 to an impressive 2.83 trillion by 2023. This represents a remarkable growth of over 125%.

On the other hand, Exelixis, a U.S.-based biotechnology company, has demonstrated a dynamic growth pattern. Starting with a modest gross profit of around 23 million in 2014, Exelixis experienced a staggering increase, reaching nearly 1.76 billion by 2023. This exponential growth highlights a more than 7,500% increase, underscoring Exelixis's rapid expansion in the biotech sector.

While Takeda's growth is steady and substantial, Exelixis's trajectory is a testament to the potential of emerging biotech firms. However, data for 2024 is incomplete, leaving room for speculation on future trends.